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S U M M A R Y
Objectives: The aim of the present study was to assess the usefulness of insertion element IS1395 for
differentiation of Mycobacterium xenopi, an increasingly common opportunistic human pathogen.
Methods: Fifty-two isolates obtained from 51 patients in Poland in 1996, 1997, and 1999, were analyzed
by IS1395 restriction fragment length polymorphism (RFLP), and their susceptibilities to 11 anti-
tuberculosis drugs were also determined.
Results: IS1395-associated banding patterns of the isolates were not highly polymorphic; the RFLP
patterns displayed several bands in common. Nevertheless, 44 of the 52 isolates were clearly
distinguishable from each other. Only eight strains (15.4%) occurred in four clusters of two identical
clones, one of which comprised two isolates obtained from one patient with a 12-month interval. The
remaining six patients with clustered strains showed no apparent epidemiologic links with the other
patients from the same cluster, and theyweremost likely infected by the same environmental source. No
noticeable difference in RFLP pattern or IS1395 copy number between drug-sensitive and drug-resistant
strains was shown. A high proportion (84.6%) of strains resistant to at least one drug was found, and 7.7%
were resistant to more than three drugs.
Conclusions: The stability and utility of IS1395 for further detailed epidemiological investigations of M.
xenopi was conﬁrmed and extended.
 2011 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Mycobacterium xenopi is a slow-growing non-tuberculous
mycobacterium (NTM). It is a well-known opportunistic pathogen
commonly associatedwith humandisease, notablywith pulmonary
infection, causing a clinical presentation said to be similar to disease
caused by Mycobacterium tuberculosis complex (MTC) species or
Mycobacterium avium-intarcellulare.1 Extrapulmonary and dissemi-
nated infections have also been recorded.2,3 A predisposing factor is
impaired immunity, either local (e.g., pre-existing pulmonary
disease) or systemic (e.g., hematologic malignancy, immunosup-
pressive medication, or HIV/AIDS).2,4 Isolation of M. xenopi from
clinical samples may be indicative of clinical disease, although
colonization without disease often occurs. This also applies to HIV-
infected patients who can have concurrent illnesses.5,6
There are regional differences in the isolation of M. xenopi.
While uncommon in the USA, it is among the most frequently
isolated NTM species in various regions of Canada and Europe.3,7,8* Corresponding author. Tel.: +48 42 272 3610; fax: +48 42 272 3630.
E-mail address: jdziadek@cbm.pan.pl (J. Dziadek).
1 Equal contributors.
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doi:10.1016/j.ijid.2010.10.008According to a recent survey of NTM isolates, the frequency of
identiﬁcation ofM. xenopi has increased worldwide over a 20-year
period.9 Like other potentially pathogenic mycobacteria,M. xenopi
is widely present in the environment, especially in tap water.10,11
Dailloux et al. hypothesized that bioﬁlms may be considered
reservoirs for the proliferation of mycobacteria in water distribu-
tion systems and contributors to the continuous bacteriological
contamination of the water via an erosion process.12 Transmission
to humans is believed to originate from the environment, through
aerosol inhalation or ingestion. Human-to-human transmission
and transmission from animal reservoirs have not been demon-
strated. Detailed investigation of animal and environmental
reservoirs, as well as the determination of transmission routes
and infection modes, requires precise strain-typing techniques.
Restriction fragment length polymorphism (RFLP) upon hy-
bridization to speciﬁc probes is a widely used molecular
epidemiological method for characterization of strains by genomic
ﬁngerprinting. A number of repeated DNA sequences have been
successfully used as genetic markers for the identiﬁcation of
mycobacterial species or strain differentiation.13 An element
related to MTC-speciﬁc IS1081 was shown to be present in M.
xenopi.14,15 Screening of a partialM. xenopi genomic librarywith an
IS1081 probe resulted in isolation of a new insertion sequence,ses. Published by Elsevier Ltd. All rights reserved.
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to be a useful epidemiological tool for typing of M. xenopi strains
providing a diversity of RFLP patterns.16
In this study, M. xenopi clinical isolates from Poland were
analyzed by the RFLP method using a probe for IS1395. Drug
resistance proﬁles using a wide group of antibiotics were also
determined and compared to molecular typing data.
2. Materials and methods
2.1. Patient characteristics
Patient information including date of isolation, HIV status, and
standard demographic data were recorded. Fifty-two isolates from
51 patients were analyzed. These patients represent 73% of the
patients examined with bacteriologic conﬁrmation of M. xenopi
infection and 0.7% of all examined patients (positive and negative
cultures) at the National Tuberculosis and Lung Diseases Institute
(NTLDI) in Warsaw, Poland, in 1996, 1997, and 1999 (Table 1).
Patients originated from different regions of the country. The
patients were aged between 27 and 77 years, and 71% were aged
between 20 and 60 years. Most of the patients (59%) were men. All
were HIV-negative.
2.2. Bacterial strains
The 52M. xenopi strains analyzed in the present study were
provided by the NTLDI in Warsaw, which is the national
tuberculosis reference laboratory. In one case, a second isolate
was obtained with a 12-month interval from a single patient, and
these two repeat isolates were included in the analysis. The species
identiﬁcation of the strains was based on standard microbiological
tests. All the strains were examined for their susceptibility to 11
drugs: isoniazid, rifampin, streptomycin, ethambutol, oﬂoxacin,
amikacin, ethionamide, capreomycin, clofazimine, rifabutin, and
erythromycin using Lo¨wenstein–Jensen medium and the BACTEC
460-TB system (Becton Dickinson, Sparks, MD, USA).
2.3. PCR ampliﬁcation
Sequence analysis of the insertion element IS1395 (GenBank
accession No. U35051) allowed the selection of primers XN1 (50-
ACGAGGCTTTCCAAGTCGCAGG-30) and XN2 (50-TCGTTGGTGAC-
CAGCGCCAC-30) at positions 439–460 and 730–749, respectively.
The two primers XN1 and XN2 were used to generate a 311-bp
probe for RFLP analysis. Puriﬁed chromosomal DNA fromM. xenopi
strain 145 was used as a template for the IS1395 probe
ampliﬁcation. DNAs fromM. xenopi 50/98 and the reference strain
M. tuberculosis H37Rv served as controls for PCR speciﬁcity.
Ampliﬁcation reactions were performed with 50-ml volumes
containing 2.5 mM each deoxynucleoside triphosphate, 0.2mM of
each primer, 2 U of Taq DNA polymerase (Promega, Madison, WI,
USA), and 100 ng of template DNA in the commercial buffer
(50 mM KCl, 10 mM Tris–HCl pH 9.0, 0.1% Triton X-100, 1.5 mMTable 1
Numbers of patients investigated at the National Tuberculosis and Lung Diseases
Institute in 1996, 1997, and 1999 and enrolled in this study
Year All patients
investigated
Bacteriologic
conﬁrmation of
M. xenopi infection
RFLP analysis of
M. xenopi strains
1996 2967 24 22
1997 2158 18 14
1999 2452 28 16
Total 7577 70 52
RFLP, restriction fragment length polymorphism.MgCl2) (Promega). In addition, the reaction mixtures included
dimethyl sulfoxide (DMSO) at three different concentrations: 0%,
3%, or 6%. The cycling parameters consisted of initial denaturation
at 94 8C for 2 min, followed by 35 cycles of denaturation at 94 8C for
1 min, annealing at 60 8C or 63 8C for 1 min, and extension at 72 8C
for 1 min, with additional 5 min of annealing and 10 min of
elongation steps after the last cycle. The PCR programs were
performed on an MJ Research thermocycler (Waltham, MA, USA).
Ampliﬁcation products were analyzed by electrophoresis on a 7%
polyacrylamide gel and detected by ethidium bromide staining.
2.4. RFLP analysis
The 311-bp probe within IS1395 was prepared as described
above and recovered from polyacrylamide gel by overnight elution
at 37 8C with 10 mM ethylenediaminetetraacetic acid (EDTA),
0.5 M ammonium acetate, 10 mM magnesium acetate, and 0.1%
sodium dodecyl sulfate (SDS). DNA was puriﬁed by phenol/
chloroform extraction followed by ethanol precipitation, and
labeled with horseradish peroxidase using the ECL system
(Amersham).
Chromosomal DNA from theM. xenopi isolates was prepared as
described previously,17 and digestedwith restriction endonuclease
PvuII. DNA fragments were resolved by electrophoresis on a 1%
agarose gel at 12–15 V/cm and transferred to a nylon membrane
(Hybond-N+; Amersham) using the capillary method. The mem-
brane was hybridized overnight at 42 8C with the probe, then
washed twice for 20 min at 42 8C with 6 M urea, 0.4% SDS, and
0.5  standard saline citrate (SSC), and ﬁnally washed twice for
5 min at room temperature with 2  SSC. The peroxidase-labeled
probe was detected with the ECL detection system (Amersham).
The IS1395 RFLP patterns were examined visually, scanned and
compared using ScanPack software (version 3.0; Biometra,
Germany). Comparisons of patterns were done by the unweighted
pair group method analysis (UPGMA) using the Dice coefﬁcient
with the parameter settings at 1.0% band position tolerance with
optimization. Amolecular cluster was deﬁned as a series of isolates
exhibiting 100% identical IS1395 banding patterns.
3. Results
3.1. Designation and PCR ampliﬁcation of IS1395 probe
To study the RFLP of the repetitive element among M. xenopi
strains, primers XN1 and XN2 were designed to produce a 311-bp
IS1395 internal probe (positions 439–749).
Denaturation (94 8C) and extension (72 8C) temperatures, as
well as the number of 35 ampliﬁcation cycles, were maintained
throughout two different PCR programs used to obtain the probe.
In the preliminary experiments, ampliﬁcation reactions were
performed at the annealing temperature of 60 8C. Under these
reaction conditions, a variable number of non-speciﬁc products
were seen in DNA extracted from twoM. xenopi strains in addition
to the expected one. Moreover, non-speciﬁc amplicons (including
that of 311 bp) appeared in the control sample containing DNA
from M. tuberculosis H37Rv (data not shown). Increasing the
stringency to 63 8C allowed for the ampliﬁcation of the expected
311-bp fragment within IS1395 in DNA templates from M. xenopi
only (Figure 1, lanes 5–6 and 8–9), and yielded very few non-
speciﬁc products of both wrong sizes and very low concentrations
with DNA template from M. tuberculosis H37Rv (Figure 1, lane 3).
Also, it proved necessary to include DMSO in a reaction mixture.
This agent facilitates denaturation of double-stranded DNA
(dsDNA), especially with high G+C content characteristic of
mycobacteria. In the absence of DMSO, the expected 311-bp
fragment of IS1395 was not produced (Figure 1, lanes 4 and 7).
[(Figure_1)TD$FIG]
Figure 1. Polyacrylamide gel electrophoresis of PCR products from Mycobacterium
tuberculosisH37Rv (lanes 1–3),Mycobacterium xenopi 145 (lanes 4–6), andM. xenopi
50/98 (lanes 7–9) ampliﬁed at 63 8C annealingwith primers XN1 and XN2 and using
no DMSO (lanes 1, 4 and 7), 3% DMSO (lanes 2, 5 and 8), or 6% DMSO (lanes 3, 6 and
9). Lane 10, molecular size standard (pUC19 digested with HaeIII). Arrow indicates
the position of a 311-bp IS1395 fragment.
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The 52 strains were analyzed by RFLP with IS1395 as a
hybridization probe. PvuII was used for digestion of genomic DNA
as IS1395 did not contain a corresponding restriction site.[(Figure_2)TD$FIG]
Figure 2. IS1395 RFLP patterns of the 52Mycobacterium xenopi isolates and the correspon
right. The similarity among the patterns is indicated as a percentage above the dendroThe copy number of IS1395 in each of the strains was
determined from the number of bands hybridizing to the probe,
and ranged from 6 to 13 (Figure 2). The majority of the strains
(n = 46; 88.5%) contained 9–12 copies, with a mean of 10
bands.
The DNA ﬁngerprints generated were not highly variable; the
RFLP patterns displayed several bands in common. In the region of
2.5 kbp, all the studied strains showed three bands. Also, a
computer-assisted similarity analysis demonstrated seven clus-
ters of patterns with a high (95%) level of relatedness (Figure 2).
Five of these comprised two patterns each that differed by the
presence of one additional band. Despite the relatively low
diversity of the patterns, the IS1395 RFLP technique allowed for
sufﬁcient discrimination of the strains tested. Forty-eight differ-
ent IS1395 DNA ﬁngerprint patterns were observed in the 52
strains analyzed. Of the 48 patterns, only four were identical for
two strains each, whereas the remaining 44 patterns (92% of
strains)were found only once each in this investigation (Figure 2).
Three pairs of identical strains were isolated at different times
from different patients presumably representing cases of infec-
tion from a common, most likely environmental, source. The
fourth cluster comprised two isolates obtained with a 12-month
interval fromone patient, but it did not lead to changes in the RFLP
pattern (Figure 2). This observation conﬁrmed sufﬁcient stability
of IS1395 as an epidemiological marker useful in typing of M.
xenopi strains.ding dendrogram. Drug resistance proﬁles of the analyzed isolates are given on the
gram. *Two consecutive isolates from the same patient.
Table 2
Drug resistance proﬁles of Mycobacterium xenopi strains
Groupa Drug No. (%) of resistant strains isolated
1996 1997 1999 Total
I RMP 0 0 1 (6.3) 1 (1.9)
EMB 0 0 3 (18.8) 3 (5.8)
AMC 0 1 (7.1) 0 1 (1.9)
ETA 1 (4.5) 0 0 1 (1.9)
SM 3 (13.6) 0 0 3 (5.8)
INH 5 (22.7) 2 (14.3) 0 7 (13.5)
II INH, RMP 2 (9.1) 2 (14.3) 1 (6.3) 5 (9.6)
INH, SM 1 (4.5) 0 0 1 (1.9)
INH, EMB 1 (4.5) 3 (21.4) 1 (6.3) 5 (9.6)
RMP, EMB 1 (4.5) 0 6 (37.5) 7 (13.5)
III INH, RMP, EMB 1 (4.5) 1 (7.1) 3 (18.8) 5 (9.6)
INH, RMP, AMC 0 1 (7.1) 0 1 (1.9)
IV Resistant to more than three drugs 0 3 (21.4) 1 (6.3) 4 (7.7)
Total 15/22 (68.2) 13/14 (92.9) 16/16 (100) 44/52 (84.6)
RMP, rifampin; EMB, ethambutol; AMC, amikacin; ETA, ethionamide; SM, streptomycin; INH, isoniazid.
a Groups I, II, III, and IV include strains resistant to one, two, three, or more than three drugs, respectively.
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Among 52M. xenopi strains, only eight (15.4%) were susceptible
to all 11 drugs tested. The drug resistance patterns of the
remaining 44 (84.6%) strains are given in Table 2. Sixteen
(30.8%) strains were found to be resistant to at least one anti-
tuberculosis drug, and 28 strains (53.8%) were resistant to two or
more drugs. There was a large increase in the number of resistant
strains identiﬁed in 1999 (100%) compared to 1996 (68.2%), and
most of these (37.5%) were resistant to both rifampin (RMP) and
ethambutol (EMB).
IS1395 RFLP patterns of 44 drug-resistant strains were
compared with those of eight drug-sensitive strains. The results
showed no noticeable difference in banding pattern or copy
number of IS1395 between drug-sensitive and drug-resistant
strains. Strains with different drug resistance proﬁles were found
in the same clusters. One cluster consisted of two sensitive isolates
consecutively obtained from one patient. On the other hand,
strains with identical drug resistance proﬁles displayed different
RFLP patterns (Figure 2). These results suggest that resistance ofM.
xenopi to one or more anti-tuberculosis drugs does not correlate
with the IS1395 DNA ﬁngerprints.
4. Discussion
Among the NTM,M. xenopi is an increasingly common cause of
both pulmonary and disseminated disease in humans, yet very
little is known about its molecular epidemiology, the possibility of
human-to-human transmission of these mycobacteria, and impli-
cations for disease control. Since there is no obligation to report
NTM infections in Poland, a systematic review of NTM is lacking.
The available data covering the studied period revealed that
Mycobacterium kansasii,M. avium complex, andM. xenopiwere the
most frequent NTM isolates in Poland in 1991–2001.18,19 In the
present study, 52 clinical isolates of M. xenopi were subjected to
molecular characterization based on the RFLP of the insertion
element IS1395.
IS1395 is a member of the Staphylococcus aureus IS256 family of
insertion sequences. It displays 86% nucleotide sequence and 89%
amino acid identity with MTC-speciﬁc IS1081.16 The high
percentage homology between these IS256 family members was
the most probable cause of unspeciﬁc PCR ampliﬁcation of a 311-
bp DNA fragment inM. tuberculosis at the annealing temperature of
60 8C in the present study. To eliminate this false-positive result
during ampliﬁcation of IS1395 probe for RFLP analysis, we
conducted the reaction at higher stringency (63 8C), which yieldedthe expected product in DNA templates from M. xenopi only.
Previous investigation of the host range of IS1395 by Southern blot
analysis revealed additional IS1395-related IS256 repeated
sequences inM. avium,Mycobacterium gordonae, andMycobacteri-
um celatum.16 Similarly, homology between IS3-like elements from
several NTM species and a central region of MTC-speciﬁc IS6110,
which overlaps the internationally agreed RFLP probe, has been
reported.20 This homologywas probably the cause of false-positive
results we observed previously in an IS6110-based PCR assay for
MTC when performed at 60 8C or 55 8C annealing temperatures.17
Results of our previous study and this study on PCRs performed at
high stringencies (65 8C and 63 8C, respectively) support the
observations of others – that insertion sequence-targeted PCR
assays should be carefully designed and evaluated to speciﬁcally
detect mycobacterial species.20,21
Data on DNA polymorphism within M. xenopi are scarce in the
literature and include restriction fragment analysis and hybrid-
ization with probes of the insertion elements IS139516 or IS108115
to detect RFLPs among the strains. RFLP patterns were found to be
identical using IS1081 or IS1395 as probes.16 This study further
evaluated the IS1395 as an epidemiological marker on a large set of
M. xenopi strains and extended previous data. In accordance with
observations from an RFLP study of M. xenopi isolates from the
USA,15 the isolates investigated in the present study carried from 6
to 13 copies of the IS1395 element (median 10). This is less than the
3–18 copies (median 14) described in a French study.16 The
authors also reported that 15 out of 19 studied strains showed
either ﬁve or two copies of IS1395 in the region of 2.5 kbp.
Interestingly, all 52 isolates tested here had three bands in that
region, indicating their close relationship. Nevertheless, DNA
ﬁngerprinting analysis revealed 48 distinct patterns among the
strains studied, which is similar to the level of polymorphism
described by others. Collins observed seven different IS1081 RFLP
patterns among 10M. xenopi strains isolated from humans.15
Picardeau et al., using the IS1395 probe, detected speciﬁc RFLP
patterns for 19 clinical strains of M. xenopi despite the generally
low level of polymorphism generated.16
In the present study, four pairs of identical IS1395 RFLP patterns
were encountered. One of these clusters comprised two consecu-
tive isolates obtained with a 12-month interval from one patient,
thus conﬁrming the stability of IS1395 and its utility as an
epidemiological marker. It is generally accepted thatM. tuberculo-
sis strains with unique RFLP proﬁles upon hybridization with the
IS6110 probe indicate cases of endogenous reactivation of
previously acquired infection, and clustered strains are likely to
represent epidemiologically linked cases of recently transmitted
K. Lenart et al. / International Journal of Infectious Diseases 15 (2011) e321–e325 e325disease.22 In contrast, whereas clusters of cases tend to occur,
active transmission of NTM has never been demonstrated and
environmental sources of infection are likely, yet it cannot be
excluded.1 Tracing the transmission routes of NTM is very difﬁcult
due to their ubiquitous presence in the environment. Based on the
available epidemiological data, no direct link between clustered
patients in this study could be proved and they were most likely
infected by the same environmental source ofM. xenopi. Since data
on the clinical signiﬁcance of the infections were not available, it
cannot be excluded that some of the cases might have resulted
from contamination of clinical specimens and nosocomial acqui-
sition from the hospital water supply.23
NTM species have been shown to have natural resistance to
many anti-tuberculosis drugs that, together with the frequently
observed lack of correlation between in vitro drug susceptibility
testing and clinical response, makes treatment difﬁcult.1,24 In the
present study, resistance to at least one anti-tuberculosis drug was
found in 84.6% of the 52M. xenopi strains, but in 100% of strains
from 1999. Monoresistance to isoniazid (INH) as well as resistance
to both RMP and EMB were predominant (13.5% each). The strains
resistant to three drugs accounted for 11.5% (resistance to INH,
RMP, and EMB was predominant in this group and accounted for
9.6%), whereas 7.7% of all the tested strains were resistant to more
than three anti-tuberculosis drugs. The four strains comprising this
latter group had different resistance patterns, but all were resistant
to INH, RMP, and EMB. Similar resistance proﬁles were encoun-
teredwith comparable frequencies in other studies.6,24 Recent data
suggest that INH is not as effective as other drugs against
pulmonary M. xenopi,25 but RMP and EMB, which are recom-
mended as the cornerstone of treatment for this pathogen, did not
prove more effective in susceptibility testing in this study.
Nevertheless, in vitro resistance does not preclude an in vivo
efﬁcacy, hence RMP and EMB cannot be excluded from the ﬁrst-
line treatment of M. xenopi infections. Also, we did not observe
gross differences in RFLP patterns between drug-resistant and
drug-sensitive strains, a ﬁnding similar to our previous results on
M. tuberculosis.26
This study demonstrates on a large set ofM. xenopi strains that
RFLP analysiswith the IS1395 probe provides a useful tool for strain
typing, based on variations of both copy number and distribution
of this insertion element within the genome. The results indicate a
lack of correlation between RFLP type and drug resistance proﬁle
for M. xenopi strains. Due to the paucity of data available for this
increasingly common pathogen, further studies that focus on
better delineating the transmission routes and identifying sources
of infection are needed.
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